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Summary 
Natural killer cells express clonally distributed receptors specific for major histocompatibility 
complex class I  molecules.  The human  leukocyte antigen  (HLA)-C-specific receptors have 
been molecularly identified and cloned. They exist not only as inhibitory (p58) but also as acti- 
vatory (1050) receptors. Here we show that p50 and p58 are highly homologous in their extra- 
cellular regions formed by two  Ig-like domains.  In contrast, major differences exist in their 
transmembrane and cytoplasmic portions. Whereas p58 displays a 76-84-amino acid cytoplas- 
mic  tail  containing an  unusual  antigen  receptor activation motif, p50  is  characterized by a 
shorter 39-amino acid tail.  In addition, whereas p58 has a nonpolar transmembrane portion, 
p50 contains the charged amino acid Lys. These data strongly suggest that receptors with iden- 
tical HLA-C allele specificity can mediate functions of opposite sign owing to their different 
transmembrane/cytoplasmic portions. 
T 
he cytolytic activity of NK cells is regulated by several 
clonally  distributed  inhibitory  receptors  specific  for 
different groups of HLA class I andes. Interaction between 
these NK receptors and HLA class I molecules leads  to in- 
hibition of the NK-mediated target cell lysis (1--4). The re- 
ceptors specific for two  distinct groups  of HLA-C alleles 
have been molecularly identified as p58 molecules, which 
react with either GL183 (5) or EB6 mAb (6). p58-encod- 
ing genes have recently been isolated and cloned (7). They 
encode for type 1 transmembrane proteins, which belong 
to the Ig supeffamily. They are characterized by two extra- 
cellular  Ig-hke  domains  and  display  a  high  level  of se- 
quence homology. Recently, additional  50-kD molecular 
forms of EB6 or GL183 mAb-reactive receptors have been 
identified. They display the same HLA-C allele specificity 
of the  corresponding p58  receptors but mediate  NK  cell 
triggering rather  than  inhibition  (8).  p50  receptors were 
found to be expressed only in some donors and to display a 
clonal distribution. Importantly, single NK cells did not co- 
express p58  and p50  receptors with  an  identical  HLA-C 
specificity (8). The protein backbone of p58 or p50 mole- 
cules has been shown to be 42 and 36 kD, respectively, af- 
ter  deglycosylation.  These  data,  together  with  identical 
HLA-C specificity and mAb reactivity, suggested that p58 
and  p50  could be  homologous  in  their  extracellular do- 
mains but different in their intracellular portions. Cloning 
of several p58-homologous genes revealed the existence of 
molecules displaying cytoplasmic tails  of different length. 
Here we show that, different from p58, the activatory p50 
receptors are characterized by a short intracytoplasmic tail 
associated with a transmembrane portion containing a polar 
residue. 
Materials  and Methods 
Isolation  of EB6 + or GL183 §  NK  Clones  and  Definition  of the 
Function of their Receptors.  EB6 § or GL183  § NK cell clones were 
isolated as previously described (4). Screening of clones for the 
expression of triggering (p50) or inhibitory (p58) receptors was 
performed by cytolytic tests using P815 target cells in a redirected 
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with Cw3 or Cw4 alleles as described in detail elsewhere  (8). 
Amplification of Specific cDNAs fiom NK Cell Clones.  Total RNA 
was extracted  using RNAzol (Cinna/Biotecx, Friendswood, TX) 
by  standard  procedure,  cDNA  was  obtained by  reverse  tran- 
scriptase  (RT)  reaction using oligo  dT  priming. Primers  used 
for cDNA  amplification  were  5'-ACCTACAGATGCTTCGG 
(common up,  nucleotides (nt)  583-599),  5'-AAAACACAGT- 
GATCCAATTA (C, nt. 913-932), and 5'-GTTCCG(CT)GTA- 
CACGATGA (E,  nt. 986-1003).  Each RT-PCR reaction con- 
tained 0.1  I-~M of control primers specific for the HLA-C locus 
[C1,  5'-GACG(AC)CG(AC)GAGTCC(AG)AGAGG;  and  C2, 
5'-CG(GT)CCTCGCTCTGGTTGTAG]  and 0.5 IxM of group- 
specific primers.  The set of primers common up/C was used in a 
30-cycle PCR, including 15 cycles at 30 s at 94~  30 s at 60~ 
and 30 s at 72~  and 15 cycles of 30 s at 94~  30 s at 50~  and 
30  s at 72~  followed by a final extension of 7  rain at 72~ 
PCR using the primer pair common up/E was carried out for 30 
cycles of 30 s at 94~  30 s at 60~  and 30 s at 72~  followed by 
a final extension of 7 rain at 72~  cDNA fragments  were sub- 
cloned into pCRII vector (Invitrogen, San Diego, CA)  and se- 
quenced. 
Dot Blot Hybridization.  Amplified  fragments  were  denatur- 
ated  in 0.45  N  NaOH,  spotted  into nylon membrane (Gene- 
Screen Plus; Dupont, NEN, Boston, MA) and hybridized with 
the  following  32p-labeled  oligonucleotides:  5'-CAGTGGT- 
CAAA(CA)TCCCTTTCA (K-Lys nt. 752-772), 5'-CAGACA- 
CCTGCATGTTCTG (K2 nt. 723-741), and 5'-TGACTCTC- 
CATACGAGTGG (K4 nt. 609-627). Hybridization was carried 
out for 4 h at 56~  in 0.1% SDS, 5 ￿  Denhardt's solution, and 
5 ￿  SSPE (probes Lys and K4), or 3 X SSPE (probe K2). Mem- 
branes were washed in 0.1% SDS and 0.1  ￿  SSPE  for 10 min at 
room temperature and for 10 min at 42~ 
Isolation of Full-Length cDNAs.  The sequences  of the forward 
primers used to obtain complete open reading frame (ORF) am- 
plification products were  5'-ATGTCGCTCATGGTCG (SP1), 
5'-ATGTCGCTCATGGTCATCAT  (SP2), and 5'-ATGTCG- 
CTCTTGTTCG (SP3). The  PCR  cycling condition used for 
the sets of primers  SP1/C, SP2/C, and SP3/C was  15 cycles of 
20 s at 94~  30 s at 60~  30 s at 72~  followed by 15 cycles of 
20 s at 94~  30 s at 55~  and 30 s at 72~  followed by a final 
extension of 7 rain at 72~  5' end nucleotide sequences of EB6- 
ActI and i83-ActI cDNAs were checked by rapid amplification 
ofcDNA ends (RACE) (9). 
Transient Transfectants.  The monkey COS cell line (5 ￿  105/ 
plate) was transfected by the DEAE-dextran method with differ- 
ent cDNA constructs  (10): RSV.5gpt/c147.11,  RSV.5gpt/EB6- 
ActI,  RSV.5gpt/c16.11,  and  RSV.5gpt/183-ActI.  After  48  h, 
transfectants were trypsinized,  stained with EB6 or GL183 mAb, 
followed by a PE-conjugated goat antibody to mouse IgG1, and 
analyzed  by a  FACSort  |  (Becton Dickinson &  Co.,  Mountain 
View, CA). 
Stable Transfectants.  Jurkat cells (2 ￿  107) were transfected by 
electroporation  (960  IxF/250  V)  with  the  cDNA  construct 
RSV.5gpt/c142  or RSV.5gpt/EB6-ActI. 48  h  after electropora- 
tion, cells were selected in mycophenolic acid and xantine-con- 
taining medium (10 ~g/ml each).  3-4 wk later,  cells were ana- 
lyzed for cell surface expression ofp58/p50 molecules. 
Immunoprecipitation and Deglycosylation  Experiments.  Jurkat  trans- 
fectants were lysed in 1% NP-40 lysis buffer and immunoprecipi- 
tated with EB6 mAb coupled to CNBr-Sepharose. Samples were 
fractionated  in a 8.5% SDS-PAGE, blotted on a polyvinylidene 
difluoride  membrane, and analyzed  by Western blot with 12sI- 
EB6 mAb (8). Surface 12SI-labeled  (lactoperoxidase)Jurkat  trans- 
fectants were lysed in 1% NP-40 and immunoprecipitated with 
EB6 mAb coupled with CNBr-Sepharose. Undigested or N-gly- 
canase-digested  molecules were analyzed on SDS-PAGE (8). 
Results  and Discussion 
p58  and  p50  Receptors Correlate  with  Different  Types  of 
Transmembrane and Intracytoplasmic Portions.  NK cell clones 
expressing  either  the  activatory  (p50)  or  the  inhibitory 
(p58) form of EB6 or GL183 mAb-reactive receptor were 
used to  analyze whether  a  correlation exists between the 
receptor function and the type oftransmembrane/cytoplas- 
mic portion. To this end, a panel of PCR primers specific 
for unique sequences of genes encoding for either short or 
long cytoplasmic tails has been designed. The PCR primers 
used included (a)  a  common forward primer annealing at 
the  5'  end of the  sequences encoding for  the  transmem- 
brahe portions (common up);  (b)  a backward primer spe- 
cific for the short (39-amino acid) tail (primer C); and (c) a 
backward primer specific for the long (76-84-amino acid) 
tail  (primer E).  The  common up/C  primer combination 
was found to amplify a 350-bp fragment, whereas the com- 
mon up/E  combination amplified a  421-bp  fragment.  In 
NK clones expressing pS0 receptors (either EB6 or GL183), 
a 350-bp fragment was consistently amplified by the com- 
mon up/C primer combination. In contrast, in clones ex- 
pressing p58  receptors,  the  421-bp  fragment was  always 
amplified by the common up/E primer combination (Fig. 
Figure 1.  Amplification  of specific cDNAs from NK cell clones ex- 
pressing p50 or p58 receptors. (A) Common up/C and common up/E 
amplified fragments are shown. (Lanes 1 and 7) Clone 82G16 (p50 EB6); 
(lanes 2 and 8)  clone PA4 (p50 EB6); (lanes 3 and 9)  clone DF (pS0 
GL183); (lanes 4 and 10) clone 1F32 (p58 EB6); (lanes 5 and 1I) clone 
A4.12 (p58 GL183); (lanes 6 and 12) clone A1.20 (p58 GL183). As con- 
trol, a 160-bp HLA-C fragment  was coamplified. (B) The common up/C 
amplified fragments  from the NK clones 1:82G16, 2:PA4, and 3:DF were 
hybridized with K-Lys, K4, and K2 probes, whereas the common up/E 
cDNAs amplified  from the NK clones 10:1 F32, 11:A4.12, and 12:A1.20 
were hybridized  only with K-Lys. 
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Figure 2.  Cell surface expression of EB6- or GL183 mAb-reactive proteins in cell transfectants.  (A) COS cell transfectants.  COS cells were trypsinized, 
stained with EB6 or GL183 mAb, followed by a PE-conjugated goat antibody to mouse IgG1, and analyzed by FACSort  |  Isotype-matched mouse IgG 
were used as controls.  CeLls were transfected with the following cDNA constructs:  RSV.5gpt/c147.11  (inhibitory EB6)  (a and e), R.SV.5gpt/EB6-ActI 
(activatory  EB6) (b and/'), RSV.5gpt/cl6.11  (inhibitory EB6) (c and g), and RSV.5gpt/183-Actl  (activatory  GL183) (d and h). (B)Jurkat cell transfectants. 
Jurkat cells were transfected with the cDNA construct P,.SV.5gpt/c142  (inhibitory EB6) or R.SV.5gpt/EB6-Actl  (activatory EB6) and analyzed for cell 
surface  expression of p58/p50  molecules by using EB6 (a and b) or GL183 (c and d) mAb as above. In each panel, lgG1 control has been overlayed, and 
the percentage of positive cells is indicated. 
t  A).  Over  40  amplified  350-bp  fragments,  derived  from 
14  different p50 +  NK clones, were further subcloned and 
sequenced.  At least five different sequences could be iden- 
tified,  all  containing  the  Lys  codon  AAA  in  the  reading 
frame of cDNAs encoding for the transmembrane portion. 
To investigate further whether this codon was typical of all 
amplified 350-bp fragments, an oligonucleotide probe spe- 
cific  for  the  transmembrane  encoding  sequence  was  de- 
signed.  This probe, termed K-Lys, was found to hybridize 
with  all  common up/C-amplified  products  but  not with 
the common up/E ones (Fig.  1 B). 
Isolation of Full-Length cDNAs Encoding  for Activatory p50 
Receptors.  mRNA  encoding  for  p50  receptors  was  re- 
verse transcribed, amplified, and cloned by P,.T-PCR from 
Signal S  eq~enc~  ] 
Consensus  NSL~SMAC  VGFFLI~AW  PHEGVI~S  LLAHPOpLVK  SEETVILQCW  SDVRFEHFLL  HREGKFKDTL  HLIGE 
pEB6 47.11  ...L ................................  R ................  N ..........  M.B...  R... 
pEB6cl.42  ...LF  ................................................  M ..........  M.N...  R... 
p183cl.43  ....................................  R ..................................... 
p183c16  ........  V ..............................................  O .................. 
p183ActI  ...................  G  .............................................  Y ........ 
pEB6ACt  I  ...T ................................  R ................  M ..........  M.N...  R... 
Consensus  HI~VSKAI~  SIGPI~QDLA  OTYRC~S~T  HSpyQLSAPS  DPLDMTGL  ~EKPSLSAOp  GPT~ESV  TLSCS 
pEB6 47.11  ............  SR.T  ...................  V ...........  I ...........  L  ........  N ...... 
pEB6cl.  42 
p183r 
p183CL6 
p183Actl 
pEB6Act  I 
75 
75 
75 
75 
75 
75 
75 
150 
150 
............  SR.T  ...................  V ...........  I ....................  N ......  150 
...........................................................................  150 
...........................................................................  150 
...........................................................................  150 
............  SRoR  ...............................  I ....................  N ......  150 
Consensus  SRSSYDMYHI, SR,EGBAImRRFSAGPL~TFQADFpLGP&TBGC~s  SFRI~PYHWS  NSSDPLLVSVTGNPS  225 
pEB6 47.11  ....................  LP ..............................  S .......  K ..............  225 
I~B6cI.42  ....................  LP ..............................  H .......  K ..............  225 
p183cl,43  ..................  C ...................................................  I ....  225 
plB3cl6  ...........................................................................  225 
p183ActI  ...........................................................................  225 
pEB6ActI  ....................  LP..T  ........  N ..........................  K ..............  225 
I  T ....  mbrane  I 
Consensus  NSWPSPTEPS  SKTONPI~BVLIC~fSV~/II  LFILLLFFLL  HRWCSNKEXAAVM~EPAGNRTVNSEDS~QDPOE  300 
pEB6 47.11  ...................  I ..............  - ....................  S .....  A ............  299 
pEB6cl.42  ...................  I ..............  - .................  S .....  A ............  299 
p183ci.43  ...................  I ..............  - ....................  S .....  A ............  299 
pi$3016  ...........  E ....................  V .............  R ..........  300 
p183ActI  ...........................  K.  P~TI~...  .......  ...,C  .....  .  .....................  H,  300 
pEB6Act  I  ...........  E ...............  K.  P.TI  ...........  D ..........................  H..  300 
Consensus  VTYAOLN~CV  ~RKITRPS  QRPKTPPTDI  IV~LPNAE  SRSKVVSCP  349 
pEB6  47.11  ...T .............................................  348 
pEB6cl.42  ...T .............................................  348 
p183ci.43  ...T .............................  A ...............  348 
p183c16  ........................................  P ........  341 
plfl3ActI  .S..- ............................................  304 
pEB6Act~  .S..- ............................................  304 
Figure  3.  Alignment  of amino acid sequences  cod- 
ing for GL183 mAb-reactive molecules (clone 6, clone 
43,  183-ActI)  or EB6  mAb-reactive  molecules  (clone 
42, 47.11, EB6-ActI). Dashes were introduced to max- 
imize  homologies.  Amino  acids  identical  to  the  con- 
sensus  are indicated by dots.  Signal peptide and trans- 
membrane  regions  are  marked;  cysteines  predicted  to 
form  Ig domains are indicated by asterisks,  cDNA se- 
quences  have been  deposited  in EMBL  with the  fol- 
lowing accession numbers: EB6-ActI X89892 and 183- 
Actl X89893.  Previously described sequences have the 
following  GenBank  accession  numbers:  clone  6, 
U24074;  clone 43, U24075;  clone 42, U24076;  clone 
47.11, U24078; clone 49, U24079. 
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obtain the complete ORF  of the corresponding genes.  To 
this end, based on the known sequences of the genes cod- 
ing  for p58  molecules,  three  forward  primers  (SP1,  SP2, 
and  SP3)  specific  for  different  signal  peptide  sequences 
were designed and used in combination with the backward 
primer  C.  By  using  the  primer  combination  SP1/C,  an 
amplified product of 932 bp was obtained exclusively from 
NK clones expressing the p50 EB6 or GL183 activatory re- 
ceptors.  The  products  amplified  from  two  representative 
clones  (PA4 and DF),  termed EB6-ActI and  183-ActI, re- 
spectively,  were  subcloned  in  the  pCP,.II  vector  and  se- 
quenced.  In Fig. 3, these sequences are compared with the 
several known p58 sequences. 
Activatory EB6 and  GLI83 Molecules Differ in their Trans- 
membrane Portions.  Probes  specific  for the  regions  flank- 
ing the AAA Lys codon of either EB6-ActI  (K4)  or  183- 
ActI (K2)  were  further  designed.  K2 and K4 probes were 
hybridized with the common up/C  PCR-amplified prod- 
ucts  obtained  from  a  panel  of NK  clones  expressing  p50 
EB6  or  GL183  activatory receptors.  A  precise  correlation 
was  found  between  hybridization  with  K2  or  K4  probes 
and the EB6 or GL183 phenotype.  Fig.  1 B shows the re- 
sults  obtained  in  three  representative  NK  cell  clones.  It is 
evident  that the K4 probe only hybridized with  the  com- 
mon up/C PCR products derived from the p50/EB6 + cell 
clones. Conversely, the K2 probe only hybridized with that 
derived from the p50/GL183 + cell clone. 
MAb  Reactivity  with  COS  Transient Cell  Transfectants. 
183-ActI  and  EB6-ActI  cDNAs  were  subcloned  in  the 
pRSV.5gpt  expression  vector  (10)  and  transiently  trans- 
fected in COS cells.  EB6-Actl transfectants were found to 
react  with  EB6  but  not with  GL183  mAb,  whereas  183- 
ActI transfectants  were stained  by GL183 but not by EB6 
mAb  (Fig.  2  A).  In  both  transfectants,  50-kD  molecules 
were  revealed  by  immunoprecipitation  experiments,  fol- 
lowed by Western blot,  using either EB6 or GL183 mAbs. 
Conversely,  58-kD  molecules  were  immunoprecipitated 
from  COS  cells  transfected  with  either  47.11  or  6.11 
cDNAs  (data  not  shown)  (7),  coding  for  p58  EB6  or 
GL183 inhibitory receptors, respectively (not shown). 
Sequence Alignment  of Different  p50  and  p58  Receptors. 
EB6-ActI and  183-ActI cDNAs were  compared with  the 
previously  described  GL183  and  EB6  cDNA  sequences 
(not  shown).  EB6-ActI did  not  correspond  to  any  of the 
known sequences,  whereas  183-ActI was  highly homolo- 
gous  to  the  previously  described  clone  49  (7).  However, 
the  ORF  of the  183-ActI  cDNA  encodes  for  a  protein 
containing, at residue 20, Gly instead of Trp.  In addition, it 
encodes for three  additional  amino  acids  (Met-Ser-Leu)  at 
the NH 2 terminus  (Fig.  3),  which appear to be  critical for 
an  efficient  expression  of  GL183  molecules  (data  not 
shown).  Alignment  of all  known  p58-related  amino  acid 
sequences  also  indicated  that  the  extracellular  regions  of 
both  EB6  and  GL183  molecules  are  highly  homologous. 
However, at least  11  amino acid residues in the extracellu- 
lar domains were unique to EB6 or GL183 molecules. 8 of 
these  residues  were  localized in  the  more  external  Ig-like 
Figure 4.  Biochemical  analysis ofp58/p50 molecules expressed by cell 
transfectants. (A) lmmunoprecipitation of  p58/p50 molecules from  Jurkat 
cells. Jurkat cells untransfected or transfected with RSV.5gpt/cl.42 and 
RSV.5gpt/EB6-ActI were lysed in 1% NP-40 lysis buffer and immuno- 
precipitated with  EB6  mAb  coupled with CNBr-Sepharose. Samples 
were size fractionated in an 8.5% SDS-PAGE and analyzed by Western 
blot with 12~I-EB6 mAb. Cell lysates of a p58  + NK clones (LM) and a 
p50 + NK clone (PA) were used as controls. On the right vertical side of 
the figure, the position of  molecular mass standard is reported. (B) N-gly- 
canase digestion. EB6 mAb immunoprecipitates from surface t2SI-labeled 
transfectants. Lanes  A and B are from RSV.5gpt/cl.42, and lanes C and D 
are from RSV.5gpt/EB6-Act-I transfectants, respectively. Samples undi- 
gested (lanes A and C) or digested with N-glycanase  (lanes B and D) were 
analyzed in an 8% SDS-PAGE under nonreducing conditions. On the 
fight vertical side of the figure, the position of molecular mass standard is 
reported. 
domain.  Both  183-ActI- and EB6-ActI-encoded proteins 
displayed a 39-amino acid cytoplasmic tail.  Moreover, they 
shared  four  unique  residues  in  their  transmembrane  por- 
tions  (one  represented  by  Lys)  not  present  in  molecules 
characterized by the 76/84-AA tails. 
Biochemical Analysis of  p50 /p58 Molecules Expressed by Jur- 
kat Cell Transfectants.  To  characterize  further  the p50  or 
p58  molecules  encoded  by  EB6-ActI  and  EB6-c142 
cDNAs  and  reactive  with  EB6  mAb,  stable  transfectants 
were  generated  in Jurkat  cells  using RSV.5gpt  constructs. 
Both transfectants were brightly stained by EB6 but not by 
GL183  mAb  (Fig.  2  B).  In addition,  EB6  mAb immuno- 
648  HLA-C~pecific Activatory NK Receptors precipitated  50-kD molecules from EB6-ActI cell transfec- 
tants  and  58-kD  molecules  from  EB6-c142  transfectants 
(Fig.  4  A).  In addition,  N-glycanase digestion  resulted  in 
molecules of 36 and 42 kD, respectively, in agreement with 
previous  data  on  EB6  activatory  or  inhibitory  molecules 
expressed by NK cell clones (8)  (Fig. 4 B). 
These data indicate that the HLA-C--specific NK recep- 
tors that mediate either cell triggering or inhibition display 
a  high  sequence  homology in  their  extracellular  domains, 
but  not  in  their  transmembrane  or  cytoplasmic  portions. 
Therefore, receptors with identical specificity and mAb re- 
activity may transduce  signals  of opposite  sign  because  of 
structural  differences  in  the  portions  involved  in  signal 
transduction. 
The finding that  11  amino acid residues  in the extracel- 
lular domains are unique  to EB6 or GL183 receptors  may 
be  related  to  the  different  HLA-C  allele  specificity  and 
mAb reactivity.  On the  other hand,  the activatory and in- 
hibitory  receptors  reacting  with  the  same  anti-p58  mAb 
only differed for 2-7 residues in their extracellular domains. 
In  contrast,  major  differences  existed  in  their  transmem- 
brahe and cytoplasmic portions.  Thus, only the transmem- 
brane portion  of the  activatory receptor  contained a polar 
(Lys)  residue,  in  association  with  a  39-amino  acid  intra- 
cytoplasmic tail.  This residue in the transmembrane portion 
of p50  molecules  represents  a  potential  site  of association 
with proteins  involved in  signal  transduction.  The inhibi- 
tory form is characterized by a 76-84-amino acid tail con- 
taining an antigen  receptor activation motif (ARAM)-like 
motif  characterized  by  tandem  Tyr-X-X-Leu  sequences 
spaced by 26 amino acids.  Notably, in the typical ARAMs 
present in the TCR-associated CD3 chains, the Tyr-X-X- 
Leu sequences are spaced by 6-8 amino acid residues  (11). 
In  contrast,  the  39-amino  acid  form  did  not  contain  the 
ARAM-like  motif  because  of  an  in-frame  stop  codon 
within the first Tyr-X-X-Leu sequence. These data suggest 
that different molecules involved in signal transduction may 
be  associated  to  the  activatory  or  inhibitory  HLA-C- 
specific receptors.  It will be of interest  to analyze whether 
NK receptors specific for other MHC class I molecules dis- 
play similar structural characteristics.  In this context, differ- 
ing experimental  evidence  in  rat  and  mouse  suggests  that 
MHC-class I-specific receptors may also deliver triggering 
signals  (12,  13).  In addition,  signaling via CD94,  the puta- 
tive  Bw6-specific  human  NK  receptor,  resulted  in  either 
NK cell triggering or inhibition (14). 
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